Show
Sort by
-
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)
-
- Journal Article
- A1
- open access
Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma : a report from the HR-NBL1/SIOPEN study
-
- Journal Article
- A1
- open access
Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients
-
Genomic amplifications and distal 6q loss are novel markers for poor survival in high-risk neuroblastoma patients
-
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial
-
Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients
-
A multilocus technique for risk evaluation of patients with neuroblastoma
-
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study
-
Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics